Rentosertib AI-designed drug shows potential to reverse biological aging

rentosertib Insilico Medicine biological age reversal idiopathic pulmonary fibrosis AI drug discovery

A study published in Nature Biotechnology reveals that rentosertib, an AI-designed drug candidate from Insilico Medicine, may have the potential to reverse biological aging markers. Originally developed to treat idiopathic pulmonary fibrosis (IPF), the drug was evaluated in a Phase IIa clinical trial involving 42 patients.

Researchers utilized six independent proteomic aging clocks to analyze longitudinal serum data. All six models consistently showed a reduction in predicted biological age among patients treated with rentosertib compared to the placebo group. In some models, the reduction in biological age was estimated to be between 3 and 6 years.

In addition to aging markers, the study observed dose-dependent improvements in Forced Vital Capacity (FVC), a key indicator of lung function. The drug, which targets the TNIK kinase, was identified using the PandaOmics platform and designed via the Chemistry42 generative AI system. Rentosertib has now progressed to Phase III clinical trials.

Entities

Alex Zhavoronkov · Harvard Medical School · Insilico Medicine · Nature Biotechnology · Peking University · Rentosertib · rentosertib

Claims

What the coverage asserts, and how many sources carry each claim.

[● 3 SOURCES] The biological age reduction in some models was estimated between 3 to 6 years. www.thebionews.net · technews.tw · www.presse-citron.net
[● 3 SOURCES] The study was published in the journal Nature Biotechnology. www.thebionews.net · technews.tw
[● 6 SOURCES] Forced Vital Capacity (FVC) showed dose-dependent improvement in patients receiving rentosertib compared to the placebo group. www.thebionews.net · technews.tw · cryptobriefing.com · time.news · www.world-today-news.com
[● 9 SOURCES] Six independent proteomic aging clock models showed a reduction in predicted biological age for patients treated with rentosertib. www.thebionews.net · technews.tw · notiziedi.it · ai.cnmo.com · www.techgear.gr · +3 more
[● 5 SOURCES] The drug was developed using the PandaOmics and Chemistry42 AI platforms. cryptobriefing.com · technews.tw · time.news · www.world-today-news.com
[● 10 SOURCES] Rentosertib is a TNIK inhibitor designed to treat idiopathic pulmonary fibrosis (IPF). www.thebionews.net · cryptobriefing.com · technews.tw · notiziedi.it · ai.cnmo.com · +4 more
[● 2 SOURCES] The drug candidate has entered Phase III clinical trials. technews.tw · cryptobriefing.com
[● 9 SOURCES] Insilico Medicine announced that its AI-discovered drug candidate, rentosertib, showed potential to reverse biological age. www.thebionews.net · technews.tw · notiziedi.it · ai.cnmo.com · www.techgear.gr · +3 more
[● 9 SOURCES] The Phase IIa study involved 42 patients with idiopathic pulmonary fibrosis. www.thebionews.net · www.ad-hoc-news.de · ai.cnmo.com · technews.tw · www.techgear.gr · +3 more